Dimensional Fund Advisors LP Raises Stock Position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Dimensional Fund Advisors LP boosted its position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) by 10.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,488,519 shares of the biopharmaceutical company's stock after acquiring an additional 227,428 shares during the period. Dimensional Fund Advisors LP owned 4.27% of Vanda Pharmaceuticals worth $11,920,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. XTX Topco Ltd bought a new position in Vanda Pharmaceuticals in the 4th quarter worth $69,000. Zacks Investment Management purchased a new stake in Vanda Pharmaceuticals in the fourth quarter worth about $74,000. SG Americas Securities LLC grew its holdings in shares of Vanda Pharmaceuticals by 26.8% during the 4th quarter. SG Americas Securities LLC now owns 25,861 shares of the biopharmaceutical company's stock worth $124,000 after acquiring an additional 5,459 shares during the period. Wells Fargo & Company MN raised its position in shares of Vanda Pharmaceuticals by 28.0% in the 4th quarter. Wells Fargo & Company MN now owns 33,509 shares of the biopharmaceutical company's stock worth $161,000 after acquiring an additional 7,339 shares in the last quarter. Finally, Brandywine Global Investment Management LLC lifted its stake in shares of Vanda Pharmaceuticals by 13.9% in the 4th quarter. Brandywine Global Investment Management LLC now owns 39,390 shares of the biopharmaceutical company's stock valued at $189,000 after purchasing an additional 4,820 shares during the period. Hedge funds and other institutional investors own 88.14% of the company's stock.

Vanda Pharmaceuticals Price Performance

VNDA stock traded down $0.02 on Thursday, reaching $3.90. 300,187 shares of the company traded hands, compared to its average volume of 724,528. The firm has a fifty day simple moving average of $4.48 and a 200-day simple moving average of $4.64. The company has a market cap of $229.67 million, a P/E ratio of -12.20 and a beta of 0.69. Vanda Pharmaceuticals Inc. has a one year low of $3.81 and a one year high of $6.75.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.05. The firm had revenue of $50.04 million during the quarter, compared to the consensus estimate of $45.13 million. Vanda Pharmaceuticals had a negative return on equity of 3.49% and a negative net margin of 9.51%. On average, sell-side analysts forecast that Vanda Pharmaceuticals Inc. will post -1.12 EPS for the current year.

Analyst Ratings Changes

VNDA has been the subject of a number of research reports. Cantor Fitzgerald reiterated an "overweight" rating and issued a $13.00 price objective on shares of Vanda Pharmaceuticals in a report on Wednesday. StockNews.com started coverage on shares of Vanda Pharmaceuticals in a research note on Wednesday, February 5th. They issued a "hold" rating for the company. Finally, HC Wainwright reissued a "buy" rating and set a $20.00 price objective on shares of Vanda Pharmaceuticals in a research note on Wednesday, May 7th.

Insider Buying and Selling at Vanda Pharmaceuticals

In other Vanda Pharmaceuticals news, CEO Mihael Hristos Polymeropoulos acquired 10,000 shares of the company's stock in a transaction that occurred on Friday, February 28th. The shares were bought at an average cost of $4.76 per share, with a total value of $47,600.00. Following the completion of the transaction, the chief executive officer now directly owns 2,361,730 shares of the company's stock, valued at approximately $11,241,834.80. This represents a 0.43% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last ninety days, insiders bought 32,000 shares of company stock worth $151,180. 10.00% of the stock is owned by corporate insiders.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.